Local changes in fractional saturation of cGMP- and cAMP-receptors in intestinal microvilli in response to cholera toxin and heat-stable Escherichia coli toxin.
Cyclic nucleotide modulation of electrolyte transport across intestinal brushborder membranes is initiated by binding of cGMP and cAMP to high-affinity receptors at the interior of the microvilli. Previously these receptors have been identified by photoaffinity-labelling techniques as regulatory domains of cGMP- and cAMP-dependent protein kinases. In the present study, the receptor concentration in isolated brushborder membrane vesicles and their fractional saturation in absorptive and secretory states of the tissue were estimated. In microvillous membrane vesicles isolated from rat small intestine in the absorptive state, about 10% of the total number of cGMP receptors (25.5 pmol/mg protein) and 40% of all cAMP receptors (28.7 pmol/mg protein) were occupied by endogenous cyclic nucleotides. Luminal exposure of the intestinal segments in vivo to heat-stable Escherichia coli toxin for 3-5 min increased the occupancy of cGMP receptors by about 5-fold without affecting receptor-bound cAMP levels. In contrast, incubation with cholera toxin for 2 h increased the fractional saturation solely of cAMP receptors by 2-fold. Addition of heat-stable E. coli toxin to cholera toxin-pretreated segments, again raising the cGMP levels by 5-fold, did not reduce the amount of receptor-bound cAMP. This finding argues against the concept that increased levels of cAMP during cholera would mimick cGMP effects on ion transport by low-affinity binding to microvillar cGMP receptors. This analysis of local changes in cyclic nucleotide levels at the microvillous level might help to explore the mechanism of action of other secretagogues or antidiarrhoeal agents and to delineate a possible compartmentation of cGMP and cAMP pools within the intestinal mucosa responding differently to external signals.
D000818:Animals; D001427:Bacterial Toxins / Q000494:pharmacology*; D002352:Carrier Proteins / Q000378:metabolism*; D002772:Cholera Toxin / Q000494:pharmacology*; D006152:Cyclic GMP / Q000378:metabolism*; D004768:Enterotoxins / Q000494:pharmacology*; D029968:Escherichia coli Proteins; D007082:Ileum / Q000378:metabolism*; D047908:Intracellular Signaling Peptides and Proteins; D007583:Jejunum / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008871:Microvilli / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000187:drug effects; D011953:Receptors, Cyclic AMP / Q000187:drug effects / Q000378:metabolism*; D013806:Theophylline / Q000494:pharmacology
D001427:Bacterial Toxins; D002352:Carrier Proteins; D004768:Enterotoxins; D029968:Escherichia coli Proteins; D047908:Intracellular Signaling Peptides and Proteins; D011956:Receptors, Cell Surface; D011953:Receptors, Cyclic AMP; C022994:cyclic GMP-binding protein; C034151:heat stable toxin (E coli); D002772:Cholera Toxin; D013806:Theophylline; D006152:Cyclic GMP